Skip to content
  • Home
  • Visit our other Journals
    • VJHemOnc
    • VJOncology
    • VJNeurology
    • VJDementia
    • VJHemOnc-E
  • About
    • Supporter
    • Expert Index
    • Editorial Board
    • Editorial Team
    • Editorial Policy
  • Contact
  • Sign up

Visit

vjhemonc logo
VJRegenMed
Logo
  • Specialties
    Hematology
    Oncology
    Musculoskeletal Disorder
    Rare Disease
    Metabolic Disorder
    Cardiovascular Disease
    Ophthalmology
    Neurology
    Infectious Disease
    View all Specialties
  • Technologies
    Cell Therapy
    MSC
    iPSC
    Gene Therapy
    Genome Editing
    Extracellular Vesicles
    CAR-T Therapy
    TCR Therapy
    Tissue-Engineering & Biomaterials
    View all Technologies
  • Topics
    Treatment
    Immuno-Oncology
    Trial Updates
    Perspectives
    Manufacturing
    COVID-19
    View all Topics
  • Conferences
    ASH 2022
    TCT 2022
    Meeting on the Med 2022
    ICLE 2022
    Advanced Therapies Week 2022
    TERMIS 2021
    ESGCT 2021
    Meeting on the Mesa 2021
    Advanced Therapies 2021
    View all Conferences
    • About
      • Supporter
      • Expert Index
      • Editorial Board
      • Editorial Team
      • Editorial Policy
    • Contact
    • Sign up

CMC

Updates in cell and gene therapy approvals 1:27
Updates in cell and gene therapy approvals
Bruce Levine • 27 Jan 2022
Addressing issues associated with bringing iSPC-derived MSCs to the clinic 0:44
Addressing issues associated with bringing iSPC-derived MSCs to the clinic
Tony Ting • 26 Jan 2022
The role of ARM in the cell and gene therapy industry 1:04
The role of ARM in the cell and gene therapy industry
Michael Lehmicke • 26 Jan 2022
Advances in cell therapies by the Cell Therapies Core 1:06
Advances in cell therapies by the Cell Therapies Core
Lavakumar Karyampudi • 27 Jan 2022
CMC challenges in cell and gene therapy manufacturing 1:29
CMC challenges in cell and gene therapy manufacturing
Michael Lehmicke • 26 Jan 2022
Addressing issues in the clinical translation of cell & gene therapies 3:07
Addressing issues in the clinical translation of cell & gene therapies
Janet Lynch Lambert • 26 Jan 2022
Remaining barriers to the translation of EV-based therapies 2:15
Remaining barriers to the translation of EV-based therapies
Eva Rohde • 10 Jun 2021
Shaping the future of CMC in cell & gene therapy 4:06
Shaping the future of CMC in cell & gene therapy
Stephen Ward • 14 Apr 2021
Regulating gene therapies: what can be learned from COVID-19? 1:46
Regulating gene therapies: what can be learned from COVID-19?
Nicole Faust • 9 Apr 2021
Tackling manufacturing challenges in advanced therapies 3:35
Tackling manufacturing challenges in advanced therapies
Matthew Durdy • 9 Apr 2021
The future impact of COVID-19 on the gene therapy sector 2:12
The future impact of COVID-19 on the gene therapy sector
Nicole Faust • 9 Apr 2021
Driving the ATMP sector forward: a regulatory perspective 4:17
Driving the ATMP sector forward: a regulatory perspective
Ana Hidalgo-Simon • 7 Apr 2021
The challenges of CMC in cell and gene therapies 2:05
The challenges of CMC in cell and gene therapies
Mike Lehmicke • 17 Mar 2021
Accelerating commercialization in advanced therapies 3:08
Accelerating commercialization in advanced therapies
Pascal Touchon • 7 Apr 2021
Journal Pages
  • Specialties
  • Technologies
  • Topics
  • Conferences
Newsletter

Receive the latest news and videos from VJRegenMed via email

Sign up
Contact Us

Contact us for more information

mmp logo

Magdalen Centre
The Oxford Science Park
Oxford OX4 4GA, United Kingdom

VJRegenMed logo
The content of VJRegenMed is intended for healthcare professionals
  • Cookie Policy
  • Privacy Policy
  • Terms of Use
  • Editorial Policy